Speaker Name: Prof. Giuseppe M.C. Rosano, Consultant Cardiologist & Professor of Cardiology, St. George's University Medical School, UK.

Explore this session to:

• Understand shift in T2DM management toward HF prevention based on major CVOTs showing reduction in HF hospitalization and CV mortality.
• Recognize early disease-modifying benefit in HFrEF supported by EMPEROR-Reduced and related HF trials showing rapid clinical improvement.
• Evaluate treatment benefit across the EF spectrum using EMPEROR-Preserved and similar studies demonstrating efficacy in HFpEF and HFmrEF.
• Learn how to initiate therapy in acute and worsening HF settings informed by EMPULSE and other acute HF trials supporting early use.
• Evaluate kidney protection and clinical positioning using EMPA-KIDNEY and supporting CKD trials alongside ESC recommendations.